Ongoing Clinical Trials for Lung Adenocarcinoma
There are currently 3 ongoing clinical trials investigating new treatments for lung adenocarcinoma. These studies are testing various immunotherapy and chemotherapy combinations in patients with advanced disease. The trials are being conducted across several European countries including Germany, Austria, France, Belgium, and Spain.
Clinical trial locations
- Austria
- Belgium
- France
- Germany
- Study Comparing Atezolizumab and Drug Combination with Pembrolizumab and Drug Combination for Patients with Advanced Lung Cancer
- Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
- Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer
- Spain
Study Comparing Atezolizumab and Drug Combination with Pembrolizumab and Drug Combination for Patients with Advanced Lung Cancer
This trial is comparing two different treatment combinations for patients with metastatic TTF-1 negative lung adenocarcinoma. TTF-1 is a protein normally found in lung cancer cells, and when it is absent, the cancer may behave differently and require specific treatment approaches.
Main inclusion criteria: Patients must be at least 18 years old with confirmed metastatic stage IV non-squamous non-small cell lung cancer that tests negative for TTF-1. They must also test negative for specific genetic changes called EGFR mutations and ALK rearrangements. Additionally, patients need to have a PD-L1 tumor proportion score below 50%, adequate liver, kidney, and bone marrow function, and an ECOG performance status of 0 or 1, meaning they are fully or mostly active. They must also have a life expectancy of at least 12 weeks and measurable cancer according to standard criteria.
Main exclusion criteria: Patients outside the specified age range or those who do not fit the specific clinical trial groups cannot participate. Vulnerable populations may also be excluded from the study.
Focus and goal: The study aims to compare survival rates between two treatment groups. One group receives atezolizumab combined with carboplatin and nab-paclitaxel, while the other receives pembrolizumab with a platinum-based drug and pemetrexed. All medications are given through intravenous infusion over a period of up to 12 months. Regular hospital visits are required for treatment administration and monitoring.
Investigational drugs: The study uses several medications including atezolizumab and pembrolizumab, which are immunotherapy drugs that help the immune system recognize and attack cancer cells. Carboplatin and other platinum-based drugs work by damaging cancer cell DNA to stop their growth. Nab-paclitaxel interferes with cancer cell division, and pemetrexed disrupts DNA and RNA synthesis in cancer cells.
Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
This trial is studying the treatment of large-cell neuroendocrine carcinoma, an aggressive type of lung cancer characterized by large, abnormal cells that grow and spread quickly.
Main inclusion criteria: Patients must be at least 18 years old with a diagnosis of locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung that cannot be cured with surgery. If the cancer has mixed types, the neuroendocrine component should make up at least 50%. Patients should not have received previous systemic therapy, although those who had curative treatment and experienced cancer recurrence at least 6 months later can participate. They must have an ECOG performance status of 0 to 2 and adequate organ function, including appropriate levels of liver enzymes, bilirubin, creatinine, neutrophils, and platelets.
Main exclusion criteria: Patients who received other cancer treatment within the last 4 weeks, those with severe allergic reactions to study drugs, active infections requiring treatment, serious medical conditions, pregnant or breastfeeding women, and those who participated in another trial within the last 4 weeks cannot join. Patients with a history of another cancer type (unless in remission for at least 5 years), untreated brain metastases, or unstable autoimmune diseases are also excluded. A history of drug or alcohol abuse within the last 12 months is also grounds for exclusion.
Focus and goal: The study evaluates how well a combination of atezolizumab with platinum-based chemotherapy (carboplatin or cisplatin) and etoposide works in improving patient survival. The treatment is given in cycles through intravenous infusion, with regular monitoring to assess cancer response and manage side effects. The trial will continue until January 2029.
Investigational drugs: Atezolizumab is an immunotherapy that blocks a protein called PD-L1, allowing the immune system to better attack cancer cells. Platinum-based drugs (carboplatin or cisplatin) damage cancer cell DNA to stop their growth. Etoposide is a chemotherapy medication that interferes with DNA inside cancer cells to prevent them from dividing.
Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer
This trial is testing a new medication called BI 907828 in patients with several types of advanced cancer, including lung adenocarcinoma. The study focuses on patients with specific genetic characteristics.
Main inclusion criteria: Patients must be at least 18 years old with advanced lung adenocarcinoma that cannot be removed by surgery. They should have tried all standard treatments that could help. Critically, patients must have specific genetic markers: MDM2 amplification (a type of genetic change) and TP53 wild-type status (a normal version of a specific gene), confirmed through tissue testing. Patients must have at least one measurable tumor, good general health (ECOG performance status of 0 or 1), adequate organ function, and a life expectancy of at least 3 months. Previous treatment side effects should be mild or resolved, except for hair loss, menstrual issues, or mild nerve problems.
Main exclusion criteria: Patients with cancer types not specified in the study, those outside the specified age range, and vulnerable populations requiring special protection cannot participate.
Focus and goal: The study evaluates the effectiveness and safety of BI 907828 when used alone in treating advanced cancers with specific genetic characteristics. Participants take the medication as an oral film-coated tablet. Throughout the study, researchers monitor how the cancer responds to treatment, how long the treatment controls the disease, patient survival, and any changes in quality of life.
Investigational drugs: BI 907828 is an investigational medication that works by inhibiting the MDM2 protein. This inhibition can activate the p53 tumor suppressor pathway, potentially stopping cancer cell growth. It is specifically designed for cancers with MDM2 amplification and TP53 wild-type status.
Summary
The three ongoing clinical trials for lung adenocarcinoma represent different approaches to treating advanced disease. Two trials focus on combining immunotherapy with chemotherapy, testing medications like atezolizumab and pembrolizumab alongside traditional chemotherapy drugs. These studies are primarily conducted in Germany and aim to improve survival rates in patients with specific cancer characteristics.
The third trial takes a different approach, testing a new targeted therapy called BI 907828 in patients with particular genetic markers. This study has a broader geographic reach across five European countries including Austria, Belgium, France, Germany, and Spain.
All three trials require patients to have advanced disease that cannot be cured with surgery and adequate organ function. They differ in their specific genetic requirements, with one trial excluding patients with TTF-1 positive cancers, another focusing on large-cell neuroendocrine carcinoma, and the third requiring MDM2 amplification with TP53 wild-type status. These trials reflect the growing trend toward personalized cancer treatment based on specific tumor characteristics and genetic profiles.
